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 Abstract 
Objectives: Improvement in localized bone regeneration are needed in order to 
avoid the use of autogenous tissue. For that purpose, the use biologic 
mediators were proposed. The aim was to test whether or not one of two 
biologic mediators, recombinant human bone morphogenetic protein-2 (rhBMP-
2) or recombinant platelet-derived growth factor (rhPDGF-BB), is superior to the 
other and to control groups for localized bone regeneration.  
Materials and Methods: Four cylinders (height: 5 mm; diameter: 7 mm) were 
screwed on the parietal and frontal bones at the cranium in 12 rabbits. The 
cylinders either received (i) deproteinized bovine bone mineral (DBBM) mixed 
rhBMP-2 (DBBM/BMP-2), (ii) DBBM mixed with rhPDGF-BB (DBBM/PDGF), (iii) 
DBBM (DBBM), and (iv) empty control (control). Rabbits were euthanized at 
2 and 8 weeks (n=6, respectively). Conventional histomorphometric and micro 
CT analyses were performed. Parametric linear mixed models were applied for 
the analyses with Bonferroni correction for the multiple group comparisons. 
Results: The area of bone regeneration (histology; AAHisto) at 2 weeks peaked 
for DBBM (41.91%) with statistically significantly greater values compared to 
DBBM/PDGF and the control group (p<0.05). At 8 weeks, mean AAHisto values 
were 96.29% (DBBM/BMP-2), 46.37% (DBBM/PDFG), 39.66% (DBBM) and 
35.98% (control) (DBBM/BMP-2 versus all groups (p<0.05)).  At 8 weeks, bone 
regeneration was greatest for DBBM/BMP-2 (35.62%) with statistically 
significant differences compared to all other groups (p<0.05). The area of bone 
regeneration (micro CT; AAm-CT) at 2 weeks amounted to 43.87% (DBBM/BMP-
2), 42.81% (DBBM/PDFG), 48.71% (DBBM) and 0.96% (control). The control 
group demonstrated statistically significantly less AAm-CT compared to all groups 
(p<0.05). At 8 weeks, mean AAm-CT values were 63.65% (DBBM/BMP-2), 
50.21% (DBBM/PDFG), 44.81% (DBBM) and 4.57% (control) (p>0.05). 
Conclusions: The use of rhBMP-2 significantly enhanced bone regeneration 
compared to all other groups including the group with rhPDGF-BB.
 Introduction 
Various techniques have shown to be successful in augmenting the 
alveolar ridge prior to implant placement. The most commonly used techniques 
are the use of autogenous block grafts (Misch et al. 1992; Raghoebar et al. 
1996) and guided bone regeneration (Dahlin et al. 1988; Buser et al. 1993; 
Hämmerle et al. 1996). Although these techniques have proven to result in 
positive clinical outcomes, they are all associated with limitations and 
drawbacks: e.g. like exposure of barrier membranes (Machtei 2001), an 
increase risk for infection (Simion et al. 1994), additional surgical donor site 
increasing patient morbidity and chair-time (Schwartz-Arad, Levin & Sigal 
2005), considerable amount of resorption during the healing process (Donos et 
al. 2005) and neurosensory disturbances after the harvesting of either chin or 
ramus block grafts (Clavero & Lundgren 2003).   
More recently, the tissue engineering principles were used to improve 
bone regeneration (Gothard et al. 2014). This field has focused on the 
investigation of bioactive molecules to induce local bone formation. The most 
promising factors for localized ridge augmentation include recombinant human 
bone morphogenetic protein-2 (rhBMP-2) and recombinant platelet-derived 
growth factor (rhPDGF-BB) (Jung, Thoma & Hämmerle 2008; Fisher et al. 2013; 
Khojasteh et al. 2013). Whereas rh-BMP-2 induces differentiation of osteoblasts 
precursors cells into more mature osteoblasts-like cells (Yamaguchi et al. 1991), 
rhPDGF-BB has a mitogenic function, increasing the quantity of cells.  
Pre-clinical models for GBR procedures have been thoroughly evaluated 
in several studies as ‘proof-of-principle’ (Donos, Dereka & Mardas 2015). This 
included DBBM (Stavropoulos et al. 2001), osteoinductive grafts (Mardas et al. 
2003b c a) and biological mediators (rhBMP-2 and rhPDGF-BB) (Zellin & Linde 
1999; Cochran et al. 2000; Jung et al. 2003; Simion et al. 2006; Hasegawa et 
al. 2008; Thoma et al. 2010; Darby & Morris 2013). However, there is a lack of 
data regarding the comparison between the two biologic mediators and 
compared to DBBM alone for localized bone regeneration in the same 
experimental model.  
The aim of the present study was therefore to test whether or not one of 
the two biologic mediators (rhBMP-2 or rhPDGF-BB) is superior to the other and 
to control groups for localized bone regeneration based histological and micro-
computed tomography (micro-CT) outcome measures. 
The hypotheses of the present study were that the use of biologic 
mediators is more favorable compared to DBBM alone for localized GBR 
procedures and that rhBMP-2 and rhPDGF-BB differ in terms of the 
regenerated area based on histological and micro-computed tomography 
(micro-CT) outcome measures.
 Materials and Methods 
Animals 
The study was designed as a randomized experimental study employing 
12 adults (12 months old) New Zealand white rabbits, weighing between 2.8 
and 3.2 kg were used. The animals were kept in a purpose-designed room for 
experimental animals and were fed a standard laboratory diet. The study was 
approved by the Institutional Animal Care and Use Committee of Yonsei 
Medical Center, Seoul, Korea (approval no.:2014-0281). 
Commercially available biological mediators were used. The preparation 
and the concentration applied was similar to a previous study utilizing rhBMP-2 
(Jung et al. 2015). 
Surgical Procedure 
Anesthesia initiated by injection of 65 mg/kg of ketamine (Ketalar, Yuhan, 
Seoul, Korea) and 4 mg/kg of xylazine (Rompun, Bayer Korea, Seoul, Korea). 
The surgical procedure and the augmentation device has previously been 
described (Jung et al., 2007). In brief, a full thickness flap was elevated to 
expose the parietal and frontal bones at the cranium. Four slits (7 mm in outer 
diameter; 1 mm sink depth) and perforations of the external cortical plate were 
prepared. Subsequently, experimental cylinders made of polycarbonate were 
screwed in each of the slits obtaining good stability. The dimension of the 
cylinders was 5 mm in height and 7 mm in outer diameter with a screw design 
towards the bone site and a small shoulder for a polycarbonate lid towards the 
covering skin flap.  
The following 4 treatment modalities were assigned to the cylinders (Fig. 1): 
(1) DBBM/BMP-2 group: rhBMP-2 (Cowellmedi, Busan, Korea) loaded 
DBBM (BioOss®, Geistlich Biomaterials, Wolhusen, Switzerland), 
(2) DBBM/PDGF group: rhPDGF-BB (GEM 21S®, Osteohealth, 
BioMimetic Therapeutics Inc., USA) loaded DBBM, 
(3) DBBM group:  DBBM mixed with saline, and 
(4) Control group: blood clot.  
 
For the DBBM/BMP-2 and DBBM/PDGF groups, 0.1 ml of rhBMP-2 
(Cowellmedi, Busan, Korea) or rhPDGF-BB (GEM 21S®, Osteohealth, 
BioMimetic Therapeutics Inc., USA) at a concentration of 0.1 mg/ml was loaded 
onto 0.07 g of DBBM granules (BioOss®, Geistlich Biomaterials, Wolhusen, 
Switzerland), respectively. Ten minutes of binding time was provided for both 
groups. For the DBBM group, 0.1 ml of saline was mixed with DBBM. 
In the first animal, the treatments were randomly assigned to the 
cylinders. In the subsequently treated animals the sequence of the treatment 
modalities was kept but the locations were stepwise rotated in a clockwise 
direction. The cylinders were left open towards the bone and closed with a lid 
towards the skin flap. Primary wound closure was obtained. The rabbits were 
sedated with barbiturates and sacrificed by an overdose of Ketamin at 2 weeks 
(6 rabbits) and 8 weeks (6 rabbits). The skull containing all 4 cylinders were 
removed and placed in 40% ethanol. 
Histological preparation 
The obtained specimens were dehydrated in a series of graded alcohol 
solutions and embedded in PMMA (polymethylmetacrylate; Merck AG, 
Darmstadt, Germany). From each specimen, a longitudinal section through the 
cylinder of 80 to 100 µm thickness was obtained by a micro cutting and grinding 
technique (EXAKT® Apparatebau, Norderstedt, Germany) adapted by Donath 
(Donath and Breuner, 1982) and stained with Hematoxylin-eosin (H&E). 
Histology and histomorphometry  
A light microscope (Keyence VHX-S90BE, Keyence Corp., Osaka, 
Japan) was used. Computer-assisted histomorphometric measurements were 
obtained using an automated image analysis system (LAS V4.3, Leica 
Microsystems, Wetzlar, Germany). One central section of each cylinder was 
used, assessing the following parameters similar to a previously published 
study (Jung et al., 2008b): 
1) the area of bone regeneration (area of bone regeneration [%] = pixel 
number of the bone area X 100/ total pixel number of the cylinder) (%; 
AAHisto); 
2) fraction of mineralized bone related to the total area (%; BHisto); 
3) fraction of bone substitute related to the total area (%; BSHisto); 
3) fraction of mineralized tissue (mineralized bone + bone substitute 
material) related to the total area (%; MTHisto); 
4) fraction of non-mineralized tissue related to the total area (%; 
NMTHisto). 
Radiographic analysis: micro-computed tomography (micro-CT) 
One examiner, not included in the study design and execution and 
unaware of the treatment modalities, performed all the measurements.  
Volumetric evaluations were done at the harvested specimens with 
Micro-CT (SkyScan1173; SKYSCAN, Kartuizersweg 3B 2550 Kontich, Belgium) 
before histological preperation. Digital micro radiographic images were acquired 
at 130 kVp and 60 µA using 1.0 mm aluminum filtration. Radiation was exposed 
at the speed of 500ms on each rotation of 0.2 degrees. High resolution images 
were taken with pixel size: 14.91 µm. For image reconstruction, images having 
2240 x 2240 pixels were taken by computer software (Nrecon, Bruker-CT, 
ver.1.5.1.2). A computer software was used to divide the bone trabecular 
pattern and marrow cavity for bony structure analysis (Ct Analyzer, Bruker-CT, 
ver.1.14.4.1). The following parameters were calculated within the cylinders:  
1) the area of bone regeneration (%; AAm-CT); 
2) fraction of mineralized bone related to the total area (%; Bm-CT); 
3) fraction of bone substitute related to the total area (%; BSm-CT); 
3) fraction of mineralized tissue related to the total area (%; MTm-CT); 
4) fraction of non-mineralized tissue related to the total area (%; NMTm-
CT). 
Statistical Analysis  
The metric variables were described with mean, median, standard 
deviation, and quartiles. The statistical comparisons of the group mean for the 
metric variables applied parametric mixed linear models since the data within a 
rabbit were dependent (clustered). The rabbit was used as random effect in 
these models. The assumptions of these models were validated qualitatively in 
view of the small sample sizes. The tests for group mean comparisons were 
Bonferroni corrected. The significance level was set at 5%. No correction for the 
multiple testing of the many parameters was applied also in view of the small 
sample size. 
 Results  
The animals did not present weight reduction or signs of local 
complications during the study period.  
Descriptive histology 
In all groups with DBBM particles, new bone formation and the bone-to-
bone substitute contact increased from 2 to 8 weeks. Outside of the cylinders, in 
some sites at 2 weeks, and in most sites at 8 weeks, massive new bone 
formation was evident located on top of the native bone (B) (Fig. 2-3). 
At 2 weeks, in the DBBM/BMP-2 group, few trabecular bone was located 
close to the native bone (B), whereas the rest of the cylinder was packed with 
DBBM particles (BS) (Fig. 2a). At 8 weeks, bone formation filled the entire 
space between the DBBM particles, reaching every corner of the cylinders. The 
cylinders were, therefore, densely packed with mineralized tissues (Fig. 3a).  
Bone formation at DBBM/PDGF sites reached a level up to half of the 
cylinder at 2 weeks (Fig. 2b). At 8 weeks, bone regeneration partially reached 
the top of the cylinder, whereas the amount of DBBM particles appeared to be 
reduced (Fig. 3b). 
In the DBBM group, bone formation reached a level of roughly one third 
of the cylinder after 2 weeks (Fig. 2c). At 8 weeks, bone formation increased 
with bone reaching the top of the cylinders (Fig. 3c). 
In the control group, bone regeneration was limited to a few trabecular on 
top of the native bone at 2 weeks (Fig. 2d). Large parts of the cylinders were 
filled with non-mineralized tissue. Bone formation increased, mostly along the 
lateral walls of the cylinder after 8 weeks, but not further coronal than half of the 
cylinder (Fig. 3d). 
Histomorphometrical analysis  
All data are presented in table 1.  
The mean AAHisto values at 2 weeks peaked for DBBM (41.91%±23.38%) 
with no statistically significant differences between the groups. At 8 weeks, 
mean AAHisto values were 96.29%±2.44% for DBBM/BMP-2, 46.37%±26.45% 
for DBBM/PDFG, 39.66%±15.06% for DBBM and 35.98%±12.48% for control 
with DBBM/BMP-2 group demonstrating statistically significantly greater AAHisto 
compared to all groups (p<0.001 vs. DBBM/PDGF, p<0.001 vs. DBBM and 
p<0.001 vs. control group) (Fig. 4). 
Bone regeneration (BHisto) at 2 weeks was minimal in all groups, but then 
increased up to 8 weeks. At 8 weeks, bone regeneration was greatest for 
DBBM/BMP-2 (35.62%±5.06%) with statistically significant differences 
compared to all other groups (p<0.001 vs. DBBM/PDGF, p<0.001 vs. DBBM 
and p<0.001 vs. control group).  
The mean values for remaining bone substitute material (BSHisto) ranged 
between 31.07%±3.55% for DBBM/BMP-2 at 2 weeks and 35.78%±2.44% for 
DBBM/PDGF at 8 weeks, which was not statistically significant (p>0.05).  
The percentage of MTHisto at 2 weeks ranged between 6.09%±4.13% for 
the control and 47.38%±8.32% for the DBBM group, with statistically significant 
differences between the control group compared to all other groups (p<0.001). 
At 8 weeks the values ranged between 13.37%±3.13% for control and 
68.08%±6.36% for DBBM/BMP-2. All differences between the groups at 8 
weeks were statistically significant (p<0.001) except between DBBM vs. 
DBBM/PDGF groups (p=0.72). 
Radiographic analysis: micro-computed tomography (micro-CT) 
All data are presented in table 2.  
The mean regenerated area (AAm-CT) at 2 weeks amounted 
43.87%±5.53% for DBBM/BMP-2, 42.81%±6.46% for DBBM/PDFG, 
48.71%±8.07% for DBBM and 0.96%±0.94% for control. The control group 
demonstrated statistically significantly less AAm-CT compared to all groups 
(p<0.001). At 8 weeks, mean AAm-CT values were 63.65%±6.1% for 
DBBM/BMP-2, 50.21%±4.34% for DBBM/PDFG, 44.81%±3.75% for DBBM and 
4.57%±1.88% for control. At 8 weeks, all differences between the groups were 
statistically significant (p<0.001) except between DBBM vs. DBBM/PDGF 
groups (p=0.27). 
Bone regeneration (Bm-CT) was minimal in all groups and the percentage 
of mineralized tissue (MTm-CT) at 2 weeks ranged between 0.84%±0.74% for 
control and 45.15%±5.46% for DBBM, with statistically significant differences 
between the control group compared to all other groups (p<0.001). At 8 weeks 
all differences between the groups were significantly different (p<0.001) except 
between DBBM/PDGF vs. DBBM groups (p=1.00).
 Discussion 
The present experimental study demonstrated that the use of DBBM in 
combination with rhBMP-2 significantly increased the area of bone regeneration 
(AAHisto), the fraction of mineralized bone related to the total area (Bm-CT) and 
the fraction of mineralized tissue related to the total area (MTm-CT). The 
DBBM/PDGF group demonstrated intermediate results between DBBM and 
DBBM/BMP-2 groups.  
The descriptive histology revealed that the use of bioactive molecules to 
induce local bone formation was not only limited to the cylinder itself, but was 
also observed outside of the cylinder. In the two groups with biologic mediators, 
the regenerated area within the cylinders reached the top of the cylinder 
(DBBM/BMP-2) or two thirds of the cylinder (DBBM/PDGF) at the later time-
points. The DBBM group was similar to the two groups with biologic mediators 
at 2 weeks. At 8 weeks, however, bone formation was limited and similar to the 
empty control group. In contrast to the groups with biologic mediators, no bone 
formation was observed outside of the cylinders in groups DBBM and the 
control group.  
For the amount of regenerated area (AAHisto), the histomorphometric 
analysis revealed at 2 weeks a similar performance between the groups. 
However, at 8 weeks, the AAHisto values for DBBM/BMP-2 were statistically 
significantly greater compared to the other groups, demonstrating almost 3 
times more bone formation compared to the control group and more than 2 
times compared to the DBBM/PDGF group. The micro-computed tomography 
analysis revealed similar outcomes for the regenerated area (AAm-CT). The 
DBBM/BMP-2, DBBM/PDGF and DBBM groups at 2 weeks rendered similar 
performance, but at 8 weeks the groups demonstrated significant differences 
between each other, and the DBBM/BMP-2 group showed the greatest 
regenerated area. These favorable outcomes for the use of rhBMP-2 are well in 
line with a number of previous investigations comparing the same biologic 
mediator in combination with various graft materials (Zellin & Linde 1999; 
Cochran et al. 2000; Jung et al. 2003; Thoma et al. 2010). In terms of rhPDGF-
BB, the results were inferior to rhBMP-2 and similar to the control group without 
the growth factor (DBBM). In an in vitro study, the release of rhPDGF-BB when 
associated with DBBM+collagen resulted in enhanced proliferation of 
osteoblastic cells compared to the carrier alone (Stephan et al. 2000). This is 
supported by another in vitro study demonstrating a fast adsorption of rhPDGF-
BB to DBBM, and, in the absence of additional proteins competing for 
adsorption, rhPDGF-BB remained attached (Thoma et al. 2012) and active 
(Stephan et al. 2000). The lack of collagen with faster degradation, and 
therefore an early release of biologic mediators, compared to DBBM (Stephan 
et al. 2000) could explain the slow bone formation at 2 weeks in the present 
study. The osteoconductive properties of DBBM could also be noted in the 
present study, corroborating with previous studies that evaluated the capability 
of DBBM to enhance new bone formation in GBR procedures (Hämmerle et al. 
1995, 1997; Stavropoulos et al. 2001).  
The fraction of mineralized bone related to the total area (BHisto) only 
rendered differences at 8 weeks. The BHisto showed greater values for 
DBBM/BMP-2 with statistically significant differences compared to all other 
groups. In the present study, just the control group presented statistically 
significant differences for the Bm-CT at 8 weeks when compared to the others 
groups. Overall, microCT analyses appeared to be less sensitive compared to 
the histologic analyses. This might be due to the threshold value that was used 
for the various tissues. Previous studies comparing histologic and microCT 
measurements demonstrated controversial data. One in vitro study showed high 
correlations between histomorphometric and microCT analysis (Thimm et al. 
2013), whereas other stated that to obtain valid conclusions, the analysis should 
be used in combination (Gielkens et al. 2008).  
The mean values for the fraction of bone substitute related to the total 
area (BSHisto) were similar at all time-points, demonstrating that the graft 
remained stable over the healing period for all augmented groups. When the 
percentage of mineralized tissue related to the total area were analyzed in both 
analysis (MTHisto and MTm-CT), no differences were found between the 
augmented groups at 2 weeks. Over the course of the following 6 weeks, a 
large amount of mineralized tissue was formed in the DBBM/BMP-2 group, 
much greater compared to the other groups. The DBBM/PDGF and DBBM 
groups rendered only a modest mineralized tissue formation.  
There is a lack of data regarding the comparison between rhBMP-2 and 
rhPDGF-BB for localized bone regeneration in the same experimental model. A 
study evaluating the efficacy of different concentrations of rhBMP-2 in rabbit 
calvaria showed a statistically significant difference in amount of newly formed 
tissue when compared to the control group without rhBMP-2 (Hasegawa et al. 
2008). A study in rabbit mandibles utilizing rhBMP-2 and DBBM showed 
outcomes in line with the data presented here, with 98% of defect area filled in 
the rhBMP-2 group (Chen et al. 2007), compared to 96.29% in the present 
study. The use of rhPDGF-BB on the rabbit calvaria in association with DBBM, 
showed a great potential to enhance bone regeneration (Thoma et al. 2012). 
Previous studies evaluated the bone regeneration using rhBMP-2 or rhPDGF-
BB with different carriers and/or study designs, and also demonstrated positive 
results in terms of the regenerated area (Wikesjö et al. 2004; Miranda et al. 
2005; Simion, Rocchietta & Dellavia 2007; Jung et al. 2009; Aghaloo et al. 
2010; Nevins et al. 2012; Xu et al. 2016). 
Although rhBMP-2 demonstrated significantly more bone formation at 8 
weeks compared to controls, it is worthwhile to point out the high costs 
associated with the use of biologic mediators, specifically rhBMP-2. Moreover, 
rhPDGF-BB is available at a much lower price (accounting for roughly a tenth of 
the costs for rhBMP-2 produced from eukaryotic system per dose and patient). 
In the present study, rhBMP-2 produced from E. coli was used, which could 
yield large quantities at low costs. When roughly calculated, the cost ratio for E. 
coli derived rhBMP-2 vs. rhPDGF-BB was 1: 3 for the same dose. The data 
indicated that with a third of the costs compared to rhBMP-2, DBBM/PDGF 
group regenerated 16.91% and 28.87% more bone than DBBM and control 
groups, respectively. The difference to DBBM/BMP-2 group was 48.15%, 
thereby leaving room for discussion on the cost-benefit ratio from a clinical point 
of view. 
 Whereas the pre-clinical model selected to run this study is well 
documented (Zellin & Linde 1999; Cochran et al. 2000; Stavropoulos et al. 
2001; Mardas et al. 2003b c a; Hasegawa et al. 2008; Thoma et al. 2010; 
Donos et al. 2015), and has a good acceptance in an ethical point of view, the 
translation of pre-clinical results should be analyzed with prudence, being an 
animal model with different physiological responses and metabolism compared 
to humans. Although the use of small animals, in this case rabbits, significantly 
differ when compared to clinical trials in humans, this type of study is commonly 
used as a ‘proof-of-principle’. Within the limitations of this study, further pre-
clinical and clinical investigations with different and more challenging defects 
are needed.  
Conclusions 
The biologic mediator rhBMP-2 was superior compared to rhPDGF-BB 
and control groups for localized bone regeneration in terms of the amount of 
regenerated bone and in terms of cost-effectiveness.  
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 Figures legends 
 
Figure 1. Bone site were prepared in each of the slits, providing primary stability 
for the PC (polycarbonate) cylinders After augmentation with the respective 
treatment modalities, the four cylinders were closed with a PC lid toward the 
covering skin-periosteal flap (a). Micro-CT 3D image of cylinders on the rabbit 
cranium (b). Digital micro radiographic images of an augmented cylinder (left) 
and an empty control cylinder (right) (c). 
Figure 2. Histologic slide at 30x magnification after 2 weeks of healing (H&E). 
DBBM/BMP-2 group cylinder (a), DBBM/PDGF group cylinder (b), DBBM group 
cylinder (c) and empty control cylinder (d). DBBM/BMP-2 = bovine-derived 
particulated bone mineral (DBBM) mixed with recombinant human bone 
morphogenetic protein-2 (rhBMP-2); DBBM/PDGF = DBBM mixed with 
recombinant platelet-derived growth factor (rhPDGF-BB). B=native bone; 
NB=new bone formation; BS=bone substitute material; OB=outside bone 
formation. 
Figure 3. Histologic slide at 30x magnification after 8 weeks of healing (H&E). 
DBBM/BMP-2 group cylinder (a), DBBM/PDGF group cylinder (b), DBBM group 
cylinder (c) and empty control cylinder (d). DBBM/BMP-2 = bovine-derived 
particulated bone mineral (DBBM) mixed with recombinant human bone 
morphogenetic protein-2 (rhBMP-2); DBBM/PDGF = DBBM mixed with 
recombinant platelet-derived growth factor (rhPDGF-BB). B=native bone; 
NB=new bone formation; BS=bone substitute material; OB=outside bone 
formation. 
Figure 4. Box Plot representing histomorphometrical values of AA (%) at 2 and 
8 weeks. 
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Table 1. Histomorphometrical analysis values (%) at 2 and 8 weeks 
 DBBM/BMP-2 DBBM/PDGF DBBM Control 
 
Mean 
(SD) 
Median 
[Q1; Q3] 
Mean 
(SD) 
Median 
[Q1; Q3] 
Mean 
(SD) 
Median 
[Q1; Q3] 
Mean 
(SD) 
Median 
[Q1; Q3] 
2 W 
AAHisto 
28.40 
(14.07) 
27.73 
[24.93; 36.71] 
18.05 
(12.77) 
17.98 
[8.27; 30.51] 
41.91 
(23.38) 
41.65 
[32.81; 50.62] 
14.01 
(10.35) 
10.01 
[7.41; 26.22] 
BHisto 
7.76 
(3.82) 
7.17 
[6.06; 10.80] 
6.44 
(2.92) 
6.07 
[4.81; 9.21] 
11.60 
(4.35) 
9.52 
[9.05; 15.42] 
6.09 
(4.13) 
5.25 
[2.17; 9.18] 
BSHisto 
31.70 
(3.55) 
30.68 
[29.56; 32.39] 
35.08 
(7.18) 
36.33 
[30.55; 40.67] 
35.78 
(6.31) 
34.65 
[32.16; 42.45] 
0 
(0) 
0 
[0; 0] 
MTHisto 
39.46a 
(3.24) 
39.77a 
[37.43; 41.55] 
41.52a 
(6.62) 
43.86a 
[39.76; 45.48] 
47.38a 
(8.32) 
45.89a 
[44.02; 51.27] 
6.09 
(4.13) 
5.25 
[2.17; 9.18] 
NMTHisto 
59.58a 
(3.36) 
59.63a 
[57.29; 61.34] 
57.55a 
(6.71) 
55.62a 
[53.41; 58.78] 
51.41a 
(8.28) 
53.20a 
[47.65; 54.53] 
93.47 
(4.26) 
94.37 
[90.05; 97.51] 
8 W 
AAHisto 
96.29abc 
(2.44) 
96.41abc 
[95.33; 97.93] 
46.37 
(26.45) 
56.91 
[18.23; 68.33] 
39.66 
(15.06) 
35.11 
[30.96; 46.86] 
35.98 
(12.48) 
33.16 
[29.40; 40.16] 
BHisto 
35.62abc 
(5.06) 
35.89abc 
[30.40; 40.33] 
14.83 
(6.75) 
16.74 
[7.47; 18.54] 
11.62 
(2.28) 
12.67 
[11.16; 12.94] 
13.37 
(3.13) 
13.14 
[10.62; 16.11] 
BSHisto 
32.46 
(7.97) 
35.12 
[32.34; 35.23] 
35.78 
(2.44) 
36.33 
[33.10; 37.05] 
33.97 
(3.22) 
33.95 
[33.07; 35.99] 
0 
(0) 
0 
[0; 0] 
MTHisto 
68.08abc 
(6.36) 
68.63abc 
[65.53; 72.43] 
50.61a 
(6.92) 
53.96a 
[43.08; 55.80] 
45.58a 
(3.71) 
46,00a 
[41.56; 47.15] 
13.37 
(3.13) 
13.14 
[10.62; 16.11] 
NMTHisto 
29.60abc 
(6.53) 
28.80abc 
[25.10; 32.14] 
48.09a 
(7.30) 
44.73a 
[42.49; 56.25] 
53.41a 
(3.84) 
53.10a 
[51.86; 57.42] 
86.02 
(3.19) 
86.25 
[83.16; 88.95] 
a: significantly different with control group (p<0.001) 
b: significantly different with DBBM group (p<0.001) 
c: significantly different with DBBM/PDGF (p<0.001) 
The area of bone regeneration (AAHisto); fraction of mineralized bone related to the total area (BHisto); fraction of bone substitute related to the total area 
(BSHisto); fraction of mineralized tissue related to the total area (MTHisto); fraction of non-mineralized tissue related to the total area (NMTHisto).  
Table 2. Radiographic analysis (micro-CT) values (%) at 2 weeks and 8 weeks 
 DBBM/BMP-2 DBBM/PDGF DBBM Control 
 
Mean 
(SD) 
Median 
[Q1; Q3] 
Mean 
(SD) 
Median 
[Q1; Q3] 
Mean 
(SD) 
Median 
[Q1; Q3] 
Mean 
(SD) 
Median 
[Q1; Q3] 
2 W 
AAm-CT 
43.87a 
(5.53) 
43.06a 
[41.23; 46.89] 
42.81a 
(6.46) 
43.15a 
[39.72; 47.06] 
48.71a 
(8.07) 
47.26a 
[45.73; 50.35] 
0.96 
(0.94) 
0.90 
[0.20; 1.07] 
Bm-CT 
0.87 
(0.28) 
0.89 
[0.69; 1.06] 
1.05 
(0.58) 
0.85 
[0.59; 1.59] 
0.81 
(0.22) 
0.72 
[0.65; 0.91] 
0.61 
(0.52) 
0.65 
[0.15; 0.71] 
BSm-CT 
29.05 
(4.50) 
29.37 
[27.11; 33.04] 
27.06 
(5.33) 
26.03 
[25.89; 28.93] 
32.64 
(5.90) 
32.57 
[28.62; 33.57] 
0 
(0) 
0 
[0;0] 
MTm-CT 
40.47a 
(4.62) 
41.31a 
[36.95; 42.68] 
38.16a 
(4.81) 
38.03a 
[35.82; 42.08] 
45.15a 
(5.46) 
44.81a 
[42.34; 48.04] 
0.84 
(0.74) 
0.86 
[0.22; 1.02] 
NMTm-CT 
13.94a 
(2.24) 
13.39a 
[13.06; 14.72] 
14.69a 
(2.52) 
13.92a 
[13.15; 15.77] 
15.26a 
(2.46) 
15.15a 
[13.40; 16.09] 
0.98 
(1.42) 
0.37 
[0.12;1.17] 
8 W 
AAm-CT 
63.65abc 
(6.10) 
63.77abc 
[58.21; 67.95] 
50.21a 
(4.34) 
51.85a 
[45.50; 52.25] 
44.81a 
(3.75) 
44.09a 
[42.82; 47.01] 
4.57 
(1.88) 
4.18 
[3.64; 5.32] 
Bm-CT 
0.87a 
(0.27) 
0.87a 
[0.63; 0.96] 
0.90a 
(0.25) 
0.84a 
[0.70; 1.04] 
1.20a 
(0.31) 
1.29a 
[0.95; 1.44] 
2.65 
(1.18) 
2.28 
[1.84; 3.37] 
BSm-CT 
49.07bc 
(6.55) 
49.51bc 
[42.83; 53.85] 
36.41 
(3.12) 
37,00 
[32.97; 38.13] 
32.04 
(3.26) 
32.12 
[29.31; 35.06] 
0 
(0) 
0 
[0; 0] 
MTm-CT 
76.52abc 
(8.18) 
77.96abc 
[74.98; 81.95] 
48.30a 
(14.04) 
50.52a 
[46.75; 57.66] 
50.13a 
(5.92) 
49.59a 
[45.14; 53.84] 
4.02 
(1.75) 
3.54 
[2.86; 5.31] 
NMTm-CT 
13.71ab 
(0.40) 
13.67ab 
[13.53; 14.05] 
12.90a 
(1.50) 
13.28a 
 [11.56; 14.12] 
11.58a 
(1.47) 
11.83a 
[10.71; 12.20] 
1.92 
(0.81) 
1.81 
[1.52; 2.42] 
a: significantly different with control group (p<0.001) 
b: significantly different with DBBM group (p<0.001) 
c: significantly different with DBBM/PDGF (p<0.001) 
The area of bone regeneration (AAm-CT); fraction of mineralized bone related to the total area (Bm-CT); fraction of bone substitute related to the total area 
(BSm-CT); fraction of mineralized tissue related to the total area (MTm-CT); fraction of non-mineralized tissue related to the total area (NMTm-CT). 
